Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GlycoMimetics, Inc.    GLYC

GLYCOMIMETICS, INC.

(GLYC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsAnalyst Reco.

GlycoMimetics : to Present at Two Upcoming Virtual Healthcare Investor Conferences

11/10/2020 | 04:01pm EST

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:

Stifel 2020 Virtual Healthcare Conference
November 16-18, 2020
GlycoMimetics presentation: Tuesday, November 17, 8:00 a.m. (EST)

Jefferies Virtual London Healthcare Conference
November 17-19, 2020
GlycoMimetics presentation: Thursday, November 19, 6:45 – 7:15 (BST)

About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage clinical development programs and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML under breakthrough therapy designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in SCD. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.


© Business Wire 2020
All news about GLYCOMIMETICS, INC.
01/07GLYCOMIMETICS : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator..
MT
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
AQ
2020GLYCOMIMETICS INC : Results of Operations and Financial Condition, Financial Sta..
AQ
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
BU
More news
Financials (USD)
Sales 2020 8,40 M - -
Net income 2020 -50,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,48x
Yield 2020 -
Capitalization 184 M 184 M -
Capi. / Sales 2020 21,9x
Capi. / Sales 2021 -
Nbr of Employees 57
Free-Float 97,8%
Chart GLYCOMIMETICS, INC.
Duration : Period :
GlycoMimetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLYCOMIMETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 10,50 $
Last Close Price 3,84 $
Spread / Highest target 291%
Spread / Average Target 173%
Spread / Lowest Target -21,9%
EPS Revisions
Managers and Directors
NameTitle
Rachel K. King President, Chief Executive Officer & Director
Timothy R. Pearson Chairman
Brian M. Hahn Chief Financial Officer & Senior Vice President
John L. Magnani Chief Scientific Officer & Senior VP-Research
Helen M. Thackray Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GLYCOMIMETICS, INC.2.13%184
GILEAD SCIENCES, INC.14.97%83 961
VERTEX PHARMACEUTICALS0.97%62 055
WUXI APPTEC CO., LTD.18.76%60 054
REGENERON PHARMACEUTICALS10.84%56 517
BEIGENE, LTD.38.16%32 552